Razoxane(Synonyms: ICRF 159)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Razoxane (Synonyms: ICRF 159)

Razoxane (ICRF 159) 是一种抗血管生成拓扑异构酶 II (topoisomerase II) 抑制剂，可用于肾细胞癌 (RCC) 的研究。

Razoxane(Synonyms: ICRF 159)

Razoxane Chemical Structure

CAS No. : 21416-67-1

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].

IC50 & Target[1]

Topoisomerase II

 

体外研究
(In Vitro)

Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley rats[2]
Dosage: 30 mg/kg or 10 mg/kg per day
Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation
Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.

分子量

268.27

Formula

C11H16N4O4
CAS 号

21416-67-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704.

    [2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务